Balyasny Asset Management
KLRS

Balyasny Asset Management’s Kalaris Therapeutics KLRS Stock Holding History

Balyasny Asset Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-693
Closed -$11.5K – 3253
2024
Q2 		$11.5K Buy
+693
New +$12.2K ﹤0.01% 2488
2023
Q1 		– Sell
-1,474
Closed -$174K – 3245
2022
Q4 		$174K Buy
+1,474
New +$250K ﹤0.01% 2160

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Balyasny Asset Management's KLRS Position: Q3 2024 in Review

Balyasny Asset Management sold out of Kalaris Therapeutics (KLRS) in Q3 2024, closing a stake of 693 shares — an estimated $11.5K sold.

Balyasny Asset Management first reported a position in KLRS in Q4 2022 and held it in 2 quarters. The position peaked at $174K in Q4 2022. 59 funds tracked by Wall St. Rank hold KLRS as of Q3 2024.

  • Balyasny Asset Management reported no remaining Kalaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 693 Kalaris Therapeutics shares in Q3 2024, an estimated $11.5K.
  • Balyasny Asset Management first reported a position in Kalaris Therapeutics in Q4 2022 and held it in 2 quarters.
  • Balyasny Asset Management's Kalaris Therapeutics position peaked at $174K in Q4 2022.
  • 59 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.